BLAINJECTIONINJECTABLEPriority Review
Approved
Oct 2022
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TECVAYLI (teclistamab) is a bispecific antibody that redirects T cells to kill multiple myeloma and AL amyloidosis cells by simultaneously binding to CD3 on T cells and B-cell maturation antigen (BSAB mechanism). It is administered as an intravenous injection and represents a novel immunotherapy approach for hematologic malignancies. The drug targets patients with relapsed or refractory disease who have limited options.
$0.29MPart D
PeakEarly-stage peak sales trajectory with minimal Part D penetration suggests significant growth opportunity; commercial team is likely scaling rapidly to drive adoption.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TECVAYLI is a recent approval (2022) in peak commercial lifecycle, suggesting strong hiring for brand management, medical science liaisons, and sales roles to drive market penetration in a competitive oncology space. Johnson & Johnson's scale and oncology focus create robust career development pathways.
Company
Worked on TECVAYLI at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.